Targeted Therapy for Metastatic Non–Small Cell Lung Cancer

The use of next-generation tyrosine kinase inhibitors has led to improved progression-free survival for patients with metastatic non–small cell lung cancer (NSCLC) and those EGFR -mutant ALK -positive tumors. Newer therapeutics can now target KRAS G12C mutations, exon 20 insertions, ERBB2 ( HER2) mutations. Patients NSCLC should undergo molecular testing these mutations as well BRAF mutations; MET 14 skipping alterations; ROS1 , RET NTRK gene rearrangements (fusions). Novel targeted are emerging at a fast pace.